Linked Life Data

15147373

Source:http://linkedlifedata.com/resource/pubmed/id/15147373

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2004-5-18
pubmed:abstractText
We retrospectively analysed toxicities and clinical results of 61 Hodgkin's lymphoma patients treated with chlorambucil, vinblastine, procarbazine, doxorubicin, bleomycin, vincristine and etoposide (ChlVPP/ABVVP), delivered in a weekly alternate schedule. Of 61 patients, 33 were in stages III-IV, 21 in stage IIB and seven in stage IIA with bulky disease or extranodal presentation. ChlVPP/ABVVP was administered for 6-8 cycles. Involved field radiotherapy (IFRT) (30-35 Gy) was delivered to 31 patients with residual disease after chemotherapy or bulky disease at diagnosis. Of 61 patients, 58 (95%) achieved complete clinical or radiological remission after chemotherapy and IFRT. With a median follow-up of 60 months, 5-year overall survival, relapse- and event-free survival were 78.8% (95% CI 68.2-91.1%), 81% (95% CI 70.6-92.2%) and 71.9% (95% CI 68.2-82.2%) respectively. Grades 3-4 neutropenia was the most relevant haematological toxicity and occurred in 82% of patients. Non-haematological toxicities were mild and reversible. No toxic deaths were recorded. One patient developed secondary acute myeloid leukaemia 1 year after ChlVPP/ABVVP. Due to the retrospective nature of this study, no definitive conclusions could be drawn about the clinical activity of ChlVPP/ABVVP. Nonetheless, clinical results seem better than those reported with standard regimens [ABVD (doxorubicin, bleomycin, vincristine, dacarbazine), MOPP (methotrexate, vincristine, procarbazine, prednisone), MOPP/ABVD] and as good as those reported using standard or escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone), with a lower degree of haematological and non-haematological toxicity. Long-term results of the ongoing randomized trial, comparing ABVD versus high-dose intensity weekly regimens will be useful to confirm our results.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0007-1048
pubmed:author
pubmed:issnType
Print
pubmed:volume
125
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
584-9
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed-meshheading:15147373-Adolescent, pubmed-meshheading:15147373-Adult, pubmed-meshheading:15147373-Aged, pubmed-meshheading:15147373-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:15147373-Bleomycin, pubmed-meshheading:15147373-Chlorambucil, pubmed-meshheading:15147373-Disease-Free Survival, pubmed-meshheading:15147373-Doxorubicin, pubmed-meshheading:15147373-Etoposide, pubmed-meshheading:15147373-Female, pubmed-meshheading:15147373-Gastrointestinal Diseases, pubmed-meshheading:15147373-Hematologic Diseases, pubmed-meshheading:15147373-Hodgkin Disease, pubmed-meshheading:15147373-Humans, pubmed-meshheading:15147373-Male, pubmed-meshheading:15147373-Middle Aged, pubmed-meshheading:15147373-Neoplasms, Second Primary, pubmed-meshheading:15147373-Procarbazine, pubmed-meshheading:15147373-Retrospective Studies, pubmed-meshheading:15147373-Survival Analysis, pubmed-meshheading:15147373-Treatment Outcome, pubmed-meshheading:15147373-Vinblastine, pubmed-meshheading:15147373-Vincristine
pubmed:year
2004
pubmed:articleTitle
ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
pubmed:affiliation
Division of Hematology-Oncology, European Institute of Oncology, Milan, Italy. giovanni.martinelli@ieo.it
pubmed:publicationType
Journal Article